Loading...
Loading...
RYTM| Name | Value |
|---|---|
| Revenues | 29.1M |
| Cost of Revenue | 3.1M |
| Gross Profit | 26.0M |
| Operating Expense | 66.4M |
| Operating I/L | -40.5M |
| Other Income/Expense | 8.7M |
| Interest Income | 4.1M |
| Pretax | -31.8M |
| Income Tax Expense | 0.5M |
| Net Income/Loss | -32.3M |
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of therapeutics for rare genetic diseases of obesity. Its lead product candidate, IMCIVREE, targets specific genetic deficiencies related to obesity, including POMC, LEPR, Bardet-Biedl, and Alström syndromes. The company is also developing setmelanotide for various genetic obesity disorders. Rhythm Pharmaceuticals has a collaborative research agreement and is focused on bringing these innovative treatments to market to address unmet medical needs in the rare genetic obesity space.
